Novocure Ltd (NVCR NASDAQ) stock market data APIs
$16.5536
-0.9(-5.4%)
as of May 6, 2026
Try our APIs with
free plan!
Novocure Ltd Financial Data Overview
Price chart is built with
Anychart
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
Prev. Close
16.5536
Open
15.6559
High
16.6092
Low
15.2952
52 wk Range
9.82-20.06
Market Cap
1 910 M
Shares Outstanding
116 M
Revenue
674 M
EPS
-0.62
Beta
0.897
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Novocure Ltd (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Novocure Ltd data using free add-ons & libraries
Get Novocure Ltd Fundamental Data
Novocure Ltd Fundamental data includes:
- Net Revenue: 674 M
- EBITDA: -166 215 008
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-04-30
- EPS/Forecast: -0.3871
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Novocure Ltd News
New
3 Overlooked Stocks Set to Soar in 2026
Smaller biotech stocks often fly under the radar. Many of them aren't consistently profitable, but some can deliver outsize growth for investors. Axsome Therapeutics(NASDAQ: AXSM) is a mid-cap with o...
3 Overlooked Stocks Set to Soar in 2026
Key Points Axsome Therapeutics and NovoCure Limited recently received FDA approvals for their therapies. MBX Biosciences is expecting late-stage clinical trial readouts this year. None of these three...
NovoCure Stock Shows Strength With RS Upgrade; Investors Should Watch For Next Entry
NovoCure stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 77 to 85. IBD's proprietary rating identifies share price action with a 1 (worst) to 99 (best) score. Is NovoCure Stock A Buy? Continue Reading
International Markets and NovoCure (NVCR): A Deep Dive for Investors
Have you looked into how NovoCure (NVCR) performed internationally during the quarter ending March 2026? Considering the widespread global presence of this oncology drug developer, examining the trend...
Get Novocure Ltd fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
